Briefings
-
How a Global R&D Convention Could Fill the Gaps Left by Today's Medical Innovation System
More than a decade after the international medical humanitarian organisation Médecins Sans Frontières (MSF) first called attention to the fatal imbalance in biomedical R&D, our field...
Last updated 25 April 2012
www.msfaccess.org/content/how-global-rd-convention-could-fill-gaps-left-todays-medical-innovation-system -
Fact Sheet: Malaria
What is Malaria? Malaria is a parasitic infection transmitted from person to person by the bite of infected female Anopheles mosquitoes. These mosquitoes usually bite from around dusk to dawn. Once...
Last updated 24 April 2012
www.msfaccess.org/content/fact-sheet-malaria -
Rationale for Tenofovir as the First Choice for First-Line Treatment of HIV
In its 2006 revision of the Guidelines on Antiretroviral Therapy for HIV Infection in Adults and Adolescents, the World Health Organization (WHO) recommended that countries...
Last updated 2 April 2012
www.msfaccess.org/content/rationale-tenofovir-first-choice-first-line-treatment-hiv-0 -
Losing Ground: How funding shortfalls and the cancellation of the Global Fund’s Round 11 are jeopardising the fight against HIV & TB
MSF calls on the stakeholders of the Global Fund to Fight AIDS, Tuberculosis, and Malaria – including its donors, Board of Directors, and Secretariat – to convene an emergency donor conference...
Last updated 19 March 2012
www.msfaccess.org/content/losing-ground-how-funding-shortfalls-and-cancellation-global-fund%E2%80%99s-round-11-are -
Combating kala azar: don’t fail the patients
Visceral leishmaniasis (VL), also known as kala azar, is a worldwide protozoal vector-borne disease, endemic in 76 countries. The annual incidence is estimated to be 250-300,000 cases, with over 90...
Last updated 15 March 2012
www.msfaccess.org/content/combating-kala-azar-don%E2%80%99t-fail-patients -
Rationale for Tenofovir as the First Choice in the First-Line Treatment of HIV
BACKGROUND In its 2006 revision of the Guidelines on Antiretroviral Therapy for HIV Infection in Adults and Adolescents, the World Health Organization (WHO) recommended that countries begin planning...
Last updated 28 February 2012
www.msfaccess.org/content/rationale-tenofovir-first-choice-first-line-treatment-hiv -
BLANK CHEQUE FOR ABUSE: ACTA & its Impact on Access to Medicines
Eight countries - Australia, Canada, Japan, Morocco, New Zealand, Singapore, South Korea and the United States – signed ACTA on 1st October 2011. The European Union and 22 of its Member States...
Last updated 17 February 2012
www.msfaccess.org/content/acta-and-its-impact-access-medicines -
The Enforcement Provisions of the EU-India FTA: Implications for Access to Medicines
MSF briefing document outlining what concerns MSF when it comes to the enforcement provisions in the EU-India FTA negotiations. Excerpt: "The EU’s proposed text on enforcement...
Last updated 10 February 2012
www.msfaccess.org/content/enforcement-provisions-eu-india-fta-implications-access-medicines -
How an FTA between the EU and India could threaten access to affordable medicines
India has been called the ‘pharmacy of the developing world’ because it produces a large number of high-quality, affordable generic medicines. Thanks in large part to competition stemming...
Last updated 9 February 2012
www.msfaccess.org/content/how-fta-between-eu-and-india-could-threaten-access-affordable-medicines -
What ‘Uniting To Combat Tropical Diseases’ Really Requires
MSF is delighted that attention is finally being paid to some of the diseases that have been neglected for too long. The US and UK’s increased support to control of worm diseases, mainly by preventive...
Last updated 30 January 2012
www.msfaccess.org/content/what-uniting-combat-tropical-diseases-really-requires
